Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer

BJU Int. 2015 Jan;115(1):163-5. doi: 10.1111/bju.12658.

Abstract

Objectives: To investigate the functional impact of the interaction of MUC1 with the epidermal growth factor receptors HER3 and HER4 in patients with bladder cancer.

Patients and methods: Using reverse transcription quantitative polymerase chain reaction, we examined MUC1 expression in 82 bladder cancer biopsies previously examined for the expression of HER3.

Results: Patients expressing high MUC1 had a favourable survival when the expression of HER3 was also high compared with when the expression of HER3 was low (P = 0.004). When MUC1 expression was low, HER3 co-expression did not influence the prognostic value of MUC1 (P = 0.488). MUC1 expression had no correlation with survival, tumour stage or grade, or to the prognostic value of HER4.

Conclusions: A high MUC1 expression was associated with a favourable prognosis in patients with bladder cancer when the expression of HER3 was also high. This suggests an involvement of HER3 in MUC1 function in bladder cancer.

Keywords: EGF system; HER3; HER4; MUC1; bladder cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cohort Studies
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Mucin-1 / genetics
  • Mucin-1 / metabolism*
  • Prognosis
  • Receptor, ErbB-3 / genetics
  • Receptor, ErbB-3 / metabolism*
  • Urinary Bladder Neoplasms / metabolism*

Substances

  • MUC1 protein, human
  • Mucin-1
  • ERBB3 protein, human
  • Receptor, ErbB-3